Results 71 to 80 of about 13,200 (163)

Development, Early Verification and Application of a North American Pediatric PBPK Model, Comparison With the North European Pediatric Population

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 10, October 2026.
ABSTRACT Physiologically based pharmacokinetic (PBPK) models are increasingly used in pediatric drug development and matching such models to the target population is an important consideration. A US pediatric PBPK model was developed incorporating four sub‐groups describing physiology and enzymatic/transporter levels for White, African American ...
Trevor N. Johnson, Fiskani Kondowe, Joyce van der Heijden, Saskia N. de Wildt, Iain Gardner, Karen Rowland Yeo   +5 more
wiley   +1 more source

lncRNA PCGEM1 strengthens anti-inflammatory and lung protective effects of montelukast sodium in children with cough-variant asthma

Brazilian Journal of Medical and Biological Research
Montelukast sodium is an effective and well-tolerated anti-asthmatic drug. Long non-coding RNAs (lncRNAs) are involved in the treatment of asthma. Therefore, this study aimed to investigate the effect of montelukast sodium on children with cough-variant ...
Zhenxing Xu, Lingling Meng, Yuejuan Xie, Wei Guo   +3 more
doaj   +1 more source

Real‐World Claims Data on Prescribed Drugs and the Associated Drug–Drug Interaction Risk in Sickle Cell Disease in the United States

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
Real‐world prescription data from 6230 adolescents and adults living with sickle cell disease (SCD) were combined with a drug–drug interaction (DDI) database to characterize the population‐level DDI risk. The findings support a DDI risk assessment for development of novel SCD therapies and during clinical management of SCD.ABSTRACTSickle cell disease ...
Rune Aabjerg Nørgaard, Laura Grenier, Peter Bruun‐Rasmussen, Ifeyinwa Osunkwo, Carolina Säll   +4 more
wiley   +1 more source

Image1_Neuropsychiatric Adverse Events of Montelukast: An Analysis of Real-World Datasets and drug−gene Interaction Network.TIFF

, 2021
Montelukast is a selective leukotriene receptor antagonist that is widely used to treat bronchial asthma and nasal allergy. To clarify the association between montelukast and neuropsychiatric adverse events (AEs), we evaluated case reports recorded ...
Eiichi Hinoi (301857), Noriaki Takeyama (11855618), Masatoshi Inden (619761), Natsumi Ueda (3207462), Yuri Nishibata (4710309), Mizuki Tanaka (4636117), Mitsuhiro Nakamura (308371), Ryogo Umetsu (4710310), Hiroyuki Tanaka (9428), Kiyoka Matsumoto (7474502), Kazuhiro Iguchi (5327258), Yoko Nakayama (11855615), Yamato Kato (4710306), Naoki Inagaki (9429), Shiori Hasegawa (2802643), Yoshinori Muto (11855639)   +15 more
core   +1 more source

From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju, HeeJae Choi, Shilpa Madari, Annie Carlisle, Ashish Sharma, Christina Kunz, Fenglei Huang   +6 more
wiley   +1 more source

Long function evolution of the montelukast and placebo group.

, 2018
Patients were subdivided in stable (110%-90% FEV1 compared to the FEV1 at the moment of CLAD diagnosis), increase (>110%) and decrease (
Dirk E. Van Raemdonck (5071331), Robin Vos (5071325), Heleen Demeyer (500670), Bart M. Vanaudenaerde (5071328), Jonas Yserbyt (2938743), Stijn E. Verleden (5071322), Geert M. Verleden (5071334), David Ruttens (5071316), Lieven J. Dupont (5071319)   +8 more
core   +1 more source

A Pilot Placebo‐Controlled Randomized Trial of Repeated High‐Dose Intravenous Magnesium Sulphate and High‐Dose Nebulized Budesonide for Severe Asthma in the Paediatric Emergency Department

Journal of Paediatrics and Child Health, Volume 62, Issue 10, Page 1948-1958, October 2026.
ABSTRACT Objective Determine if high‐dose intravenous magnesium with/without nebulized budesonide for children with acute severe asthma is safe and reduces time to medical readiness for discharge compared to standard intravenous magnesium. Methods Either 2 doses of intravenous magnesium or 1 dose and placebo, each with/without high‐dose nebulized ...
Khalid Alansari, Fatin Abou Moussa, Hadi Abu Rasheed, Bruce L. Davidson, Khalid Yousif Ibrahim, Mahmoud Alrifaai   +5 more
wiley   +1 more source

Image4_Neuropsychiatric Adverse Events of Montelukast: An Analysis of Real-World Datasets and drug−gene Interaction Network.TIFF

, 2021
Montelukast is a selective leukotriene receptor antagonist that is widely used to treat bronchial asthma and nasal allergy. To clarify the association between montelukast and neuropsychiatric adverse events (AEs), we evaluated case reports recorded ...
Eiichi Hinoi (301857), Noriaki Takeyama (11855618), Masatoshi Inden (619761), Natsumi Ueda (3207462), Yuri Nishibata (4710309), Mizuki Tanaka (4636117), Mitsuhiro Nakamura (308371), Ryogo Umetsu (4710310), Hiroyuki Tanaka (9428), Kiyoka Matsumoto (7474502), Kazuhiro Iguchi (5327258), Yoko Nakayama (11855615), Yamato Kato (4710306), Naoki Inagaki (9429), Shiori Hasegawa (2802643), Yoshinori Muto (11855639)   +15 more
core   +1 more source

Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: In an experimental rat model

, 2015
Ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic complication that can occur during assisted reproductive techniques. The aim of this study is to investigate the effects of the leukotriene receptor antagonist (montelukast) treatment in ...
Akman, Levent, Goker, Ege Nazan Tavmergen, Erbas, Oytun, Aktug, Huseyin, Tavmergen, Erol, Akdogan, Aysin, Taskiran, Dilek, Sahin, Gulnaz, Akman L., Erbas O., Goker E.N.T., Aktug H., Taskiran D., Sahin G., Akdogan A., Tavmergen E.   +15 more
core   +2 more sources

Montelukast deprescribing in outpatient specialty clinics: A single center cross-sectional study

Exploratory Research in Clinical and Social Pharmacy
Objective: To identify and evaluate montelukast deprescribing in outpatient specialty clinics. Methods: This was a single-center, retrospective, cross-sectional study conducted at an academic health system in the southern US including 21 specialty ...
David C. Foote, Jamie L. Miller, Grant H. Skrepnek, Stephen Neely, Kiya Bennett, Paul M. Boylan   +5 more
doaj   +1 more source